CAMBRIDGE, Mass. & BRISBANE, Queensland--(BUSINESS WIRE)--Vaxxas, a biotechnology company commercializing a novel vaccine delivery platform, today announced the initiation of a research project to evaluate Vaxxas’ proprietary Nanopatch™ platform for delivery of polio vaccine. The Nanopatch induces robust immune system activation by targeting vaccine to the abundant immunological cells immediately below the surface of the skin.
Help employers find you! Check out all the jobs and post your resume.
